List of Tables
Summary Table: Global Cell Viability Assays Market, by Product, Through 2023
Table 1: Manufacturer and Distributor Product Pricing Comparison
Table 2: Examples of Requirements for UV-Visible Spectrophotometers
Table 3: Classes of Biologicals
Table 4: Cell Viability Assay Market: Key Recent Investments
Table 5: Recent Studies in Cell-Based Therapeutics
Table 6: NIH Funding Estimates for Various Conditions and Diseases, 2014-2019
Table 7: Leading Causes of Burden of Diseases around the World, 2004 and 2030
Table 8: Worldwide Cancer Incidence Rate, 2018
Table 9: Global Pharmaceutical R&D Spending, 2015-2022
Table 10: Pharmaceutical Research and Manufacturers of America Member Company R&D Expenditures, 2010 and 2016
Table 11: Investments in Stem Cell Research
Table 12: Global Cell Viability Assays Market, by Product, Through 2023
Table 13: Global Cell Viability Assays Instruments Market, by Type, Through 2023
Table 14: Global Cell Viability Assays Instruments Market, by Region, Through 2023
Table 15: Global Automated Cell Counters Market, by Region, Through 2023
Table 16: Global Flow Cytometers Market, by Region, Through 2023
Table 17: Feature-wise Comparison of Conventional Flow Cytometry and Imaging Flow Cytometry
Table 18: Key Analytical Parameters Measured by Flow Cytometers in Cell Viability Research
Table 19: Global Spectrophotometers Market, by Region, Through 2023
Table 20: Types of Spectrophotometers for Cell Viability Analysis
Table 21: Global Cell Imaging and Analysis Systems Market, by Region, Through 2023
Table 22: Global Cell Viability Assays Consumables Market, by Type, Through 2023
Table 23: Global Cell Viability Assays Consumables Market, by Region, Through 2023
Table 24: Global Reagents Market, by Region, Through 2023
Table 25: Library Screening of Small-Molecule Cancer Cells by Deploying Real-Time Cell Viability Assays
Table 26: List of Applications of Reagents for Drug Discovery
Table 27: List of Research Laboratories Using Reagents for Cell Viability Testing
Table 28: Global Assay Kits Market, by Region, Through 2023
Table 29: Global Assay kits Market, by Type, Through 2023
Table 30: MTT and XTT Kits Comparison
Table 31: Cost-effective Cell Viability Assays Through In Vitro Cell Screening and Cell Death Discrimination
Table 32: Procedure for Quantification of Cell Number Through MTT Assays
Table 33: Key Benefits and Features of XTT Assay Kits Over Radioactive Isotope Techniques
Table 34: List of Recently-Developed Chymotrypsin and Homogeneous Trypsin Protease Assays, 2017
Table 35: Global Microplates Market, by Region, Through 2023
Table 36: Funding for Various Projects in Life Sciences Research, 2017-2026
Table 37: Innovation Project Funds for BRAIN 2025 Priority Verticals
Table 38: Global Cell Viability Assays Market, by Cell Type, Through 2023
Table 39: Global Human Cells Market, by Region, Through 2023
Table 40: Rate of New Cancer Cases, 2018
Table 41: Global Deaths Due to Cancer, 2018
Table 42: Global Oncology Therapeutics Investment, 2011-2021
Table 43: Global Animal Cells Market, by Region, Through 2023
Table 44: Intracellular Assays to Measure Cellular Proliferation
Table 45: Global Microbial Cells Market, by Region, Through 2023
Table 46: Regional Foodborne Disease, 2016
Table 47: Global Cell Viability Assays Market, by Application, Through 2023
Table 48: Global Clinical and Diagnostic Applications Market, by Region, Through 2023
Table 49: Global Cancer Burden, 2012 and 2030
Table 50: Global Prevalence of Dementia, 2015-2050
Table 51: Global Pharmaceutical Market, 2015 and 2020
Table 52: Pharmaceutical Spending as a Percentage of Health Spending, by Country, 2016
Table 53: Global Biologics Spending, 2011 and 2016
Table 54: Global Drug Discovery and Development Market, by Region, Through 2023
Table 55: Global Total Pharmaceutical R&D Spending, 2015-2022
Table 56: Description of Government Support for Development of New Treatments in Organizations, by Country
Table 57: Global Stem Cell Research Market, by Region, Through 2023
Table 58: Application of Stem Cells in Regenerative Medicines
Table 59: NIH Spending on Stem Cell Research, 2014-2018 (Estimated)
Table 60: Growing Investment in Different Areas of Stem Cell-Based Research in the United States, 2016 and 2017
Table 61: Ongoing Clinical Diabetes-Based Stem Cell Research
Table 62: Ongoing Clinical Leukemia-Based Stem Cell Research
Table 63: Global Basic Research Market, by Region, Through 2023
Table 64: Top U.S. Academic Institutions Spending on R&D, 2018
Table 65: Global Others Application Market, by Region, Through 2023
Table 66: Funded Projects Supporting Tissue Engineering Solutions in Cancer Research
Table 67: Global Cell Viability Assays Market, by End User, Through 2023
Table 68: Global Academic and Research Institutions Market, by Region, Through 2023
Table 69: Current Cancer Research Grants, by Type, 2018
Table 70: Global Pharmaceutical and Biotechnology Companies Market, by Region, Through 2023
Table 71: Pharmaceutical R&D Spending by U.S., 2005-2015
Table 72: R&D Spending by Seven Pharma Giants in India, 2016
Table 73: Global Hospital and Diagnostic Laboratories in Cell Viability Assays Market, by Region, Through 2023
Table 74: Death Rates Due to Cancer, 2018
Table 75: People Infected with HIV, by Region, 2014-2016
Table 76: Malaria Deaths, by Region, 2014-2016
Table 77: Global Others End User Market, by Region, Through 2023
Table 78: Clinical Applications of Flow Cytometry
Table 79: Various Cancer Research Programs
Table 80: Selected Fluorescent Dyes for Specific Staining in Flow Cytometry Applications in Food Microbiology
Table 81: Global Cell Viability Assays Market, by Region, Through 2023
Table 82: North American Cell Viability Assays Market, by Country, Through 2023
Table 83: North American Cell Viability Assays Market, by Type, Through 2023
Table 84: North American Cell Viability Assays Market, by Application, Through 2023
Table 85: North American Cell Viability Assays Market, by End User, Through 2023
Table 86: North American Cell Viability Assays Market, by Product, Through 2023
Table 87: NIH Spending on Stem Cell Research, 2013-2016
Table 88: Healthcare Expenditures in Canada, 2015 and 2040
Table 89: Distribution of Annual Budget of Canadian Institutes of Health Research, 2016
Table 90: European Cell Viability Assays Market, by Country, Through 2023
Table 91: European Cell Viability Assays Market, by Product, Through 2023
Table 92: European Cell Viability Assays Market, by End User, Through 2023
Table 93: European Cell Viability Assays Market, by Type, Through 2023
Table 94: European Cell Viability Assays Market, by Application, Through 2023
Table 95: Estimated Number of People Living with Cancer, 2015 and 2020
Table 96: Deaths from and Number of People Living with Heart and Circulatory Diseases in the United Kingdom, 2016
Table 97: Government Funding for Drug-Based Research in France, 2010 and 2016
Table 98: Rising Number of Cancer Cases in Spain, 2012 and 2015
Table 99: Hospitals and Research Centers Participating in Clinical Trials on Cancer, 2004-2016
Table 100: Rising Prevalence of Breast Cancer in Norway, 2014 and 2015
Table 101: Asia-Pacific Cell Viability Assays Market, by Country, Through 2023
Table 102: Asia-Pacific Cell Viability Assays Market, by Product, Through 2023
Table 103: Asia-Pacific Cell Viability Assays Market, by Type, Through 2023
Table 104: Asia-Pacific Cell Viability Assays Market, by End User, Through 2023
Table 105: Asia-Pacific Cell Viability Assays Market, by Application, Through 2023
Table 106: Number of People with Cancer in China, 2010-2016
Table 107: Growth in Japanese Pharmaceuticals Industry, 2010-2015
Table 108: R&D Spending by Top Seven Pharmaceutical Companies in India, 2016
Table 109: Overall ROW R&D Expenditures, by Region, 2016 and 2017
Table 110: Rest of the World Cell Viability Assays Market, by Region, Through 2023
Table 111: Rest of the World Cell Viability Assays Market, by Application, Through 2023
Table 112: Rest of the World Cell Viability Assays Market, by Type, Through 2023
Table 113: Rest of the World Cell Viability Assays Market, by End User, Through 2023
Table 114: Rest of the World Cell Viability Assays Market, by Product, Through 2023
Table 115: Deaths in Brazil Due to Cancer, by Type, 2010 and 2016
Table 116: Prevalence of Cancer in Brazil, by Type, 2010 and 2016
Table 117: Capital Raised by Israeli High-Tech Companies, 2013-2017
Table 118: Raw Material/Part Manufacturers
Table 119: Manufacturers Operating in the Cell Assays Market
Table 120: Distributors Operating in the Cell Assays Market
Table 121: Raw Material/Part Manufacturers
Table 122: Manufacturers Operating in the Cell Assays Market
Table 123: Distribution of Cell Assays Studies Globally, 2018
Table 124: Use of Competitive Strategies in the Global Cell Viability Assay Market, 2015 and 2018
Table 125: AAT Bioquest Inc.: Product Portfolio
Table 126: ABCAM: Product Portfolio
Table 127: ABCAM: Recent Developments
Table 128: Abnova: Product Portfolio
Table 129: Abnova: Recent Developments, 2015-2018
Table 130: AnaSpec Inc.: Product Portfolio
Table 131: AnaSpec Inc.: Recent Developments
Table 132: Becton, Dickinson and Co.: Product Portfolio
Table 133: Becton, Dickinson and Co.: Recent Developments
Table 134: Bio-Rad Laboratories: Product Portfolio
Table 135: Bio-Rad Laboratories: Recent Developments
Table 136: BioTek Instruments Inc.: Product Portfolio
Table 137: BioTek Instruments Inc.: Developments, April 2016-October 2018
Table 138: Biotium: Product Portfolio
Table 139: BioVision Inc.: Product Portfolio
Table 140: Cayman Chemical: Product Portfolio
Table 141: Cayman Chemical: Recent Developments
Table 142: Corning Inc.: Product Portfolio
Table 143: Creative Bioarray: Product Portfolio
Table 144: Danaher Corp.: Product Portfolio
Table 145: Danaher Corp.: Recent Developments
Table 146: Dojindo Molecular Technologies Inc.: Product Portfolio
Table 147: GE Healthcare: Product Portfolio
Table 148: Intellicyt Corp.: Product Portfolio
Table 149: Intellicyt Corp.: Recent Developments
Table 150: Merck KGAA: Product Portfolio
Table 151: Merck KGAA: Recent Developments
Table 152: MesGen: Product Portfolio
Table 153: Molecular Devices LLC: Product Portfolio
Table 154: Molecular Devices LLC: Recent Developments
Table 155: PerkinElmer Inc.: Product Portfolio
Table 156: Promega Corp.: Product Portfolio
Table 157: R&D Systems Inc.: Product Portfolio
Table 158: Takara Bio Inc.: Product Portfolio
Table 159: Takara Bio Inc.: Recent Developments
Table 160: Thermo Fisher Scientific: Product Portfolio
Table 161: VitaScientific: Product Portfolio
List of Figures
Summary Figure: Global Cell Viability Assays Market, by Product, 2017-2023
Figure 1: Research Funding for Biological Science Research Studies, 2017
Figure 2: Global Tissue Engineering and Cell Therapy Market Growth, 2009-2018
Figure 3: Global Projections for Deaths from the Top Three Chronic Diseases, 2005-2030
Figure 4: Worldwide Cancer Incidence Rate, by Type, 2018
Figure 5: Global Pharmaceutical R&D Spending, 2015-2022
Figure 6: Pharmaceutical Research and Manufacturers of America Member Company R&D Expenditures, 2010 and 2016
Figure 7: Cell Viability Assays Market, by Product
Figure 8: Types of Automated Cell Counters
Figure 9: dPCR used for Viability of Genetically Modified Organisms (GMOs)
Figure 10: Types of Consumables in the Cell Viability Assays Market
Figure 11: Classification of Assay kits
Figure 12: Conversion of Resazurin to Resorufin to Determine Cell Viability
Figure 13: Protease Activity Assays
Figure 14: Global Deaths Due to Cancer, 2018
Figure 15: Global Oncology Therapeutics Investment, 2011-2021
Figure 16: Approaches for Bacterial Viability Assessment
Figure 17: PMA-qPCR Assay and PMA treatment
Figure 18: Major Growth Factors of Global Cell Viability Assays Market, by Application
Figure 19: Cell Viability Assay Products Used in Clinical and Diagnostics Application
Figure 20: Global Cancer Burden, 2012 and 2030
Figure 21: Global Prevalence of Dementia, 2015-2050
Figure 22: Evaluation of Cell Viability Using Flow Cytometry Technique
Figure 23: Global Pharmaceutical Market, 2015 and 2020
Figure 24: Pharmaceutical Spending as a Percentage of Health Spending, 2016
Figure 25: Global Biologics Spending, 2011 and 2016
Figure 26: Global Total of Pharmaceutical R&D Spending, 2015-2022
Figure 27: Classification of Stem Cells
Figure 28: NIH Spending on Stem Cell Research, 2014-2018 (Estimated)
Figure 29: Growing Investment in Different Stem Cell-Based Research in the United States, 2016 and 2017
Figure 30: Rise in R&D Expenditures in 2018 Compared with 2017
Figure 31: Global Spending on Life Sciences R&D, 2015-2018
Figure 32: Top R&D Spending Nations in Europe, 2017 and 2018
Figure 33: Investment in Research and Innovation Through European Commission Framework Programs, 1984-2027
Figure 34: Number of Research Grants Received by European Countries, 2018
Figure 35: R&D Expenditures of the Top 20 Countries in Asia, 2017 and 2018
Figure 36: Cell Viability Assays End Users
Figure 37: Major Factors Driving Growth of the Cell Viability Assays Market
Figure 38: Generalized Scheme Representing an In Vitro Cytotoxicity Assay Protocol
Figure 39: Methods of Cell Viability Counting Used in Research Institutions
Figure 40: Usage of Flow Cytometry in the Drug Discovery and Development Process
Figure 41: U.S. Pharmaceutical R&D Spending, 2005-2015
Figure 42: R&D Spending by India’s Seven Largest Pharma Companies, 2016
Figure 43: Death Rates Due to Cancer, 2018
Figure 44: People Infected with HIV, by Region, 2014-2016
Figure 45: Malaria Deaths, by Region, 2014-2016
Figure 46: NIH Spending on Stem Cell Research, 2013-2016
Figure 47: Healthcare Expenditures in Canada, 2015 and 2040
Figure 48: Distribution of Annual Budget of Canadian Institute of Health Research, 2016
Figure 49: Estimated Number of People Living with Cancer in the U.K., 2015 vs. 2020
Figure 50: Government Funding for Drug-Based Research in France, 2010 and 2016
Figure 51: Rising Number of Cancer Cases in Spain, 2012 and 2015
Figure 52: Hospitals and Research Centers Participating in Clinical Trials on Cancer, 2004-2016
Figure 53: Rising Prevalence of Breast Cancer in Norway, 2014 and 2015
Figure 54: Number of People with Cancer in China, 2010-2016
Figure 55: Japanese Pharmaceuticals Industry, 2010-2015
Figure 56: R&D Spending by Top Seven Pharmaceutical Companies in India, 2018
Figure 57: Overall ROW R&D Expenditures, by Region, 2016 and 2017
Figure 58: Deaths in Brazil Due to Cancer, 2010 and 2016
Figure 59: Capital Raised by Israeli High-Tech Companies, 2013-2017
Figure 60: Industry Structure of Instruments Used in Cell Viability Assays Market
Figure 61: Industry Structure of Consumables Used in the Cell Viability Assays Market
Figure 62: Distribution of Cell Assays Studies Globally, 2018
Figure 63: Competitive Strategies Used in the Global Cell Viability Assay Market, 2015 and 2018
